Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series.

IF 20.3 1区医学 Q1 RHEUMATOLOGY Annals of the Rheumatic Diseases Pub Date : 2024-09-30 DOI:10.1136/ard-2024-225800

M Grace Hren, Saakshi Khattri

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用生物制剂加口服 JAK 或 TYK2 抑制剂联合治疗顽固性银屑病和银屑病关节炎：病例系列。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of the Rheumatic Diseases 医学-风湿病学

CiteScore

35.00

自引率

9.90%

发文量

3728

审稿时长

1.4 months

期刊介绍： Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

期刊最新文献

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium. Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Early identification of rheumatoid arthritis: does it induce treatment-related cost savings? New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens.